Trial Sponsored by:



Trial Summary

RECOVER-LV: The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Patients with left ventricular (LV) systolic dysfunction after myocardial infarction (MI) are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin-angiotensin-aldosterone-system (RAAS) inhibition may result in greater attenuation of adverse LV remodelling as a result of increased levels of substrates for neprilysin with vasodilatory, antihypertrophic, antifibrotic and sympatholytic effects.

This prospective, multi-centre, randomised, double-blind, active-comparator trial compared the addition of neprilysin inhibition to RAAS blockade (using sacubitril/valsartan) to RAAS blockade alone (using valsartan) in patients ≥3 months after MI with a LV ejection fraction ≤40%. 


Chief Investigator        

Dep Chief Investigator  


Trial Project Manager    

Patient Recruitment

Recruitment status: Pending